TERM ADJUNCT APPOINTMENT

| 17 June 2026

Posted: June 17, 2026

The Department of Pathology and Molecular Medicine in the Queen’s University Faculty of Health Sciences and its affiliated teaching hospitals is recruiting a Term Adjunct appointment to teach (100%) of an in-person course entitled:

Current Topics in Human Genetics (PATH425)

Term: Fall 2026 (September to December)

Location: On campus

Course level: Upper year

Format: Lectures, student presentation and student-led teaching sessions

PATH 425 is a 3.0-unit upper-year undergraduate course offered in the fall term (September to December), with a maximum enrollment of 60 students per year. The successful candidate will be responsible for coordinating the course, which emphasizes collaborative and team-based learning. Responsibilities include delivering course content, facilitating student-led and faculty-led presentations, and overseeing a teaching assistant. The course introduces students to key topics in human genetics through an interactive, discussion-driven format. Foundational concepts in clinical, molecular, and cytogenetics will be covered, providing the framework for exploring a range of contemporary issues. These include genomics and proteomics, disease susceptibility, neurobiological and cancer genetics, gene therapy, stem cell research, and more drawing from current scientific literature, the popular press, and media to foster critical thinking and group engagement.

Candidate must have a PhD, have expertise in the study of human disease, genetics, and molecular biology. Previous teaching experience in a university setting would be an asset. Preference will be given to applicants who can provide evidence of current involvement in and commitment to education through the submission of an educational dossier and the identification of referees who can attest to the applicant’s educational expertise.

Deadline for electronic receipt of applications is noon on Monday, July 6th, 2026. Applications shall include a letter of interest, complete and current curriculum vitae (CV), any other materials the applicant wishes to submit (such as a teaching dossier, teaching philosophy, teaching assessments), and the names and contact information of two referees who may be contacted, and sent electronically to:

Dr. David Berman, Professor and Head

c/o pathedcoordinator@queensu.ca

Department of Pathology and Molecular Medicine

Richardson Labs Room 202, Queen's University,

Kingston, Ontario K7L 3N6

The University invites applications from all qualified individuals. Queen's is strongly committed to employment equity, diversity, and inclusion in the workplace and encourages applications from Black, racialized/visible minority and Indigenous people, women, persons with disabilities, and 2SLGBTQ+ persons. All qualified candidates are encouraged to apply; however, in accordance with Canadian Immigration requirements, Canadian Citizens and permanent residents of Canada will be given priority. To comply with Federal laws, the University is obliged to gather statistical information about how many applicants for each job vacancy are Canadian Citizens/ permanent residents of Canada. Applicants need not identify their country of origin or citizenship, however, all applications must include one of the following statements: “I am a Canadian citizen / permanent resident of Canada”; OR, “I am not a Canadian citizen / permanent resident of Canada”. Applications that do not include this information will be deemed incomplete.

Academic staff at Queen’s University are governed by a Collective Agreement between the Queen’s University Faculty Association (QUFA) and the University, which is posted at http://qufa.ca/.

The University will provide support in its recruitment processes to applicants with disabilities, including accommodation that takes into account an applicant’s accessibility needs. If you require accommodation during the interview process, please contact Micheline McDonald (pathedcoordinator@queensu.ca)

Comprehensive profiling of clinical approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing

News

| 13 May 2026

This publication in Nature Biotechnology can be viewed here

Former DPMM PhD student and now Professor at the Fred Hutch Cancer Center at the University of Washington Dr. Taranjit Gujral has just published in Nature Biotechnology a paper entitled “Comprehensive profiling of clinical approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing”. This study provides us with a powerful resource to identify approved drugs to target oncogenic kinases in cancer. Taran has also generated a user-friendly web site called KIRHub that allows us to profile kinases and select effective inhibitors (https://kirhub.fredhutch.org/). Taran is also recruiting post-docs if you’re looking! https://research.fredhutch.org/gujral/en.html

The Gujral Lab is seeking a highly motivated and innovative Post-Doctoral Research Fellow to advance precision oncology through systems biology approaches that integrate functional screening, genomics, and computational modeling.

PMM Year In Review 2025

Spotlight

| 15 April 2026

PMM Year In Review 2025

2026 William Corbett Award

Spotlight

| 31 March 2026

We are pleased to announce that Dr. Nicholas Phillipow is the recipient of the 2026 William Corbett Award. This award is a testament of Nicholas’ diagnostic excellence and academic achievement during his studies within the Department of Pathology and Molecular Medicine.

Congratulations Nicholas!!

Articles

TERM ADJUNCT APPOINTMENT

Comprehensive profiling of clinical approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing

PMM Year In Review 2025

2026 William Corbett Award

Recent Posts